A preclinical German biotech, owned by Sweden's Simris Group AB, developing nature-derived microcystin compounds as next-generation antibody-drug conjugate payloads for targeted cancer therapy.
A preclinical German biotech, owned by Sweden's Simris Group AB, developing nature-derived microcystin compounds as next-generation antibody-drug conjugate payloads for targeted cancer therapy.
